Gold-plating Antigens

Midatech Ltd. and partner Immunotope Inc. think they have a better way to raise an immune response against cancer antigens that will be attractive to investors as a stand-alone program. This is the concept behind Syntara LLC, a 50:50 joint venture announced last week between the nanotechnology and immunotherapy companies.

Syntara will focus on the development of therapeutic vaccines to treat chronic viral infections and certain cancers. Immunotope will contribute its cancer and viral antigens, while Midatech will provide the IP and know-how for its nanoparticle delivery technology...